Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
← catalyst calendarNCT05460507 · readout in 559 d
Sponsored by Plus Therapeutics (industry) · PSTV — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
40estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-12 | actual | When the study began enrolling |
| Primary completion | 2028-03-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-01 | estimated | The whole study's end, after follow-up |
| First posted | 2022-07-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glioma
Intervention
- Drug: Retreatment Rhenium Liposome — also filed as Rhenium-186 NanoLiposome
Primary outcomes
what the primary-completion date above is the date OFAssessment of safety and tolerability of a second dose of 186RNL by CED as part of standard of care >30 days following first dose.
measured > 30 days
Overall Survival
measured 6 Months
Permalink · PSTV's whole pipeline · Catalyst calendar · Every registered study · What changed